SPO19 Antibody

What is SPOP and what cellular functions does it regulate?

SPOP (Speckle-type POZ protein) is a 42-kDa protein that functions as a substrate recognition component of the E3 ubiquitin ligase complex. It plays critical roles in protein homeostasis by targeting specific substrates for ubiquitination and subsequent degradation. SPOP is involved in multiple cellular processes including cell proliferation, apoptosis, and DNA damage response. The calculated molecular weight of SPOP is approximately 42,132 Da, although it typically appears around 39 kDa on Western blots due to its migration pattern .

What are the optimal storage conditions for anti-SPOP antibody?

Anti-SPOP antibody should be stored at -20°C for long-term preservation (up to one year). For frequent use and short-term storage (up to one month), the antibody can be stored at 4°C. It is critical to avoid repeated freeze-thaw cycles as these can compromise antibody activity and specificity. Most commercial anti-SPOP antibodies are supplied in a stabilizing solution containing PBS with 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps maintain antibody integrity during storage .

What applications has the anti-SPOP antibody been validated for?

Commercial anti-SPOP antibodies have been validated for several applications including:

• Western Blotting (WB): Typically used at dilutions of 1:500-1:2000

• Immunohistochemistry (IHC): Validated on paraffin-embedded tissues at approximately 1:200 dilution

• Immunocytochemistry (ICC): For cellular localization studies

Validation typically involves testing against known positive controls including human brain and liver tissues, as well as cell lines such as HepG2, HeLa, and 3T3 cells .

How should I optimize anti-SPOP antibody concentration for Western blotting?

Optimization of anti-SPOP antibody for Western blotting requires systematic titration to determine the ideal concentration that maximizes specific signal while minimizing background. The procedure should include:

• Prepare a dilution series (e.g., 1:500, 1:1000, 1:1500, 1:2000) of the antibody

• Use standardized protein loading (20-40 μg total protein per lane)

• Include appropriate positive controls (e.g., HepG2 or HeLa cell lysates for human SPOP)

• Include a negative control (tissue/cells known not to express SPOP)

• Maintain consistent blocking, washing, and detection conditions

Researchers have reported optimal results with anti-SPOP antibody at 1:1500 dilution for Western blotting of 3T3, HepG2, and HeLa cells . The specific concentration may require adjustment based on your detection system and the particular antibody lot.

What approaches can validate antibody specificity in experimental systems?

Validating antibody specificity is critical for experimental rigor. Multiple approaches should be employed:

• Knockdown/Knockout Validation: Compare antibody signal in wild-type versus SPOP-knockdown or knockout samples

• Peptide Competition Assay: Pre-incubate the antibody with the immunizing peptide before application

• Multiple Antibody Concordance: Use multiple antibodies targeting different SPOP epitopes

• Recombinant Protein Controls: Include purified or overexpressed SPOP protein

• Cross-Reactivity Testing: Test the antibody against closely related family members

When interpreting results, researchers should consider that antibody specificity can vary across applications (e.g., an antibody might be specific in Western blotting but show non-specific binding in IHC) .

How can I troubleshoot weak or absent signal in immunohistochemistry with anti-SPOP antibody?

When troubleshooting weak or absent IHC signal when using anti-SPOP antibody, consider the following methodological adjustments:

• Antigen Retrieval Optimization: Test multiple methods (heat-induced vs. enzymatic) and pH conditions

• Antibody Concentration: Increase antibody concentration (e.g., from 1:200 to 1:100)

• Incubation Time: Extend primary antibody incubation (overnight at 4°C instead of 1-2 hours)

• Detection System: Switch to a more sensitive detection system (e.g., polymer-based vs. ABC method)

• Fixation Assessment: Different fixation methods can affect epitope accessibility

• Tissue Thickness: Optimize section thickness (typically 4-5 μm for paraffin sections)

• Positive Control Inclusion: Always run a known positive control (e.g., human brain tissue)

How do binding kinetics inform antibody selection for particular experimental approaches?

Antibody binding kinetics, characterized by association (kon) and dissociation (koff) rates, significantly impact experimental performance. For different applications:

The relationship between binding parameters and experimental success can be leveraged through computational models that predict binding modes, enabling the design of antibodies with customized specificity profiles tailored to particular experimental needs .

Can anti-SPOP antibody be used for detecting SPOP in non-validated species?

While anti-SPOP antibody (particularly polyclonal versions) is validated for human, mouse, and rat samples, researchers often inquire about cross-reactivity with other species, such as primates. Sequence homology analysis can predict potential cross-reactivity, but experimental validation is essential.

When testing anti-SPOP antibody in non-validated species:

• Perform sequence alignment of the immunogen region (amino acids 41-90 of human SPOP) with the target species

• Start with Western blotting as it often has higher sensitivity than IHC for cross-reactivity testing

• Include appropriate positive controls (validated species) alongside the test species

• Consider using multiple applications to confirm results

• Validate with alternative methods (e.g., mass spectrometry, RNA expression)

While statistical prediction of cross-reactivity is possible, experimental validation remains the gold standard. Even high sequence homology (>90%) does not guarantee functional cross-reactivity due to potential differences in post-translational modifications or protein folding .

How can computational approaches enhance antibody specificity prediction?

Recent advances in computational modeling have revolutionized the prediction and design of antibody specificity. These approaches:

• Identify different binding modes associated with particular ligands

• Disentangle binding patterns even between chemically similar epitopes

• Enable the design of antibodies with customized specificity profiles

• Predict cross-reactivity with related proteins

Computational models combine selection experiment data with biophysics-informed modeling to optimize energy functions associated with each binding mode. This approach has successfully generated antibodies with either:

• Specific high affinity for a particular target ligand

• Cross-specificity for multiple target ligands

The integration of high-throughput sequencing data with computational analysis provides greater control over specificity profiles than traditional selection methods alone, offering a powerful toolset for designing antibodies with precisely tailored physical properties .

What controls are essential when using anti-SPOP antibody in frozen tissue sections?

When adapting anti-SPOP antibody for use in frozen tissue sections (a non-standard application), rigorous controls are essential:

• Positive Control Tissues: Include tissues with known SPOP expression patterns (e.g., brain sections)

• Negative Control Tissues: Include tissues with minimal SPOP expression

• Secondary Antibody-Only Control: Omit primary antibody to assess non-specific binding

• Isotype Control: Use matched isotype antibodies to control for non-specific binding

• Fixation Method Comparison: Compare different fixation methods (4% PFA, acetone, methanol)

• Peptide Blocking Control: Pre-incubate antibody with immunizing peptide

• Protocol Optimization: Systematically optimize blocking reagents, incubation times, and washing conditions

While anti-SPOP antibody has been validated for paraffin-embedded IHC, adaptation to frozen sections requires careful validation and may necessitate different antibody concentrations or detection methods than those established for FFPE tissues .

How can I determine if BSA in the antibody formulation affects my experimental system?

The presence of BSA (0.5%) in commercial anti-SPOP antibody formulations may interfere with certain applications, particularly:

• Mass spectrometry-based analyses where BSA peptides may confound results

• Experiments in systems sensitive to bovine proteins

• Applications requiring conjugation to the antibody

• Systems where BSA may cause non-specific binding

To address BSA-related concerns:

• Request BSA-free formulations from manufacturers (some lots of anti-SPOP antibody A02032 are available BSA-free)

• Purify the antibody using protein A/G columns to remove BSA

• Use antibody fragments (Fab or F(ab')2) that can be generated without BSA

• Include appropriate blocking controls in your experimental design

• Consider alternative antibodies if BSA interference cannot be mitigated

Special formulations typically require advance notice (approximately 3 additional days for preparation) and should be stored according to manufacturer recommendations .

How might the study of broadly neutralizing antibodies inform SPOP antibody development?

Research on broadly neutralizing antibodies, such as the SC27 antibody that neutralizes all COVID-19 variants, provides valuable insights for developing next-generation research antibodies, including those targeting SPOP:

• Epitope Selection: Targeting conserved, functionally critical epitopes increases antibody utility across experimental conditions

• Structural Biology Approaches: Using structural analysis to identify key binding sites enhances specificity

• Engineering Cross-Reactivity: Designing antibodies that recognize homologous regions across species expands research applications

• Universal Recognition Principles: Understanding how SC27 recognizes all spike protein variants despite mutations offers a framework for developing antibodies that recognize all SPOP isoforms or post-translationally modified variants

These principles could lead to the development of pan-SPOP antibodies that recognize all variants and species homologs, significantly advancing research in this field.

What methodological advances might enhance antibody development for complex protein targets?

Emerging methodologies are transforming antibody development for complex targets like SPOP:

• Phage Display with High-Throughput Sequencing: Enables the identification of antibodies with specific binding properties from large libraries

• Computational Modeling: Predicts antibody-antigen interactions and guides rational design of specificity

• Single B-Cell Sorting: Isolates naturally occurring antibodies with desired characteristics

• Machine Learning Approaches: Predicts optimal antibody sequences based on training datasets

• In Silico Epitope Mapping: Identifies accessible, unique epitopes for targeting

These approaches could be applied to develop antibodies that specifically recognize different functional domains of SPOP or distinguish between wild-type SPOP and disease-associated mutants, providing powerful tools for studying SPOP biology in health and disease .